Melanoma, Version 2.2013 Featured Updates to the NCCN Guidelines JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK Coit, D. G., Andtbacka, R., Anker, C. J., Bichakjian, C. K., Carson, W. E., Daud, A., Dimaio, D., Fleming, M. D., Guilds, V., Halpern, A. C., Hodi, F. S., Kelley, M. C., Khushalani, N. I., Kudchadkar, R. R., Lange, J. R., Lind, A., Martini, M. C., Olszanski, A. J., Pruitt, S. K., Ross, M. I., Swetter, S. M., Tanabe, K. K., Thompson, J. A., Trisal, V., Urist, M. M., McMillian, N., Ho, M. 2013; 11 (4): 395-407


The NCCN Guidelines for Melanoma provide multidisciplinary recommendations on the clinical management of patients with melanoma. This NCCN Guidelines Insights report highlights notable recent updates. Foremost of these is the exciting addition of the novel agents ipilimumab and vemurafenib for treatment of advanced melanoma. The NCCN panel also included imatinib as a treatment for KIT-mutated tumors and pegylated interferon alfa-2b as an option for adjuvant therapy. Also important are revisions to the initial stratification of early-stage lesions based on the risk of sentinel lymph node metastases, and revised recommendations on the use of sentinel lymph node biopsy for low-risk groups. Finally, the NCCN panel reached clinical consensus on clarifying the role of imaging in the workup of patients with melanoma.

View details for Web of Science ID 000317543800007